To test whether CRP can enhance the characteristics of tumorigenicity in lung cancer cells with or without EGFR mutations, we conducted proliferation, migration and metastasis assays using CL1-0 (wild-type EGFR), PC9 (EGFR exon19 deletion) and H3255 (EGFR L858R) lung adenocarcinoma cell lines treated with different CRP dosages (Fig. 5). The gene discussed is CRP; the disease is lung adenocarcinoma.